Insider Selling: Royalty Pharma (NASDAQ:RPRX) EVP Sells 20,000 Shares of Stock

Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) EVP Marshall Urist sold 20,000 shares of the business's stock in a transaction on Friday, January 9th. The stock was sold at an average price of $40.78, for a total value of $815,600.00. Following the sale, the executive vice president owned 60,000 shares in the company, valued at approximately $2,446,800. The trade was a 25.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

• How Royalty Pharma Prints Cash Without Biotech's Biggest Risks

Marshall Urist also recently made the following trade(s):

• On Friday, December 26th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $39.32, for a total value of $786,400.00.
• On Friday, December 19th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The stock was sold at an average price of $38.38, for a total transaction of $767,600.00.
• On Tuesday, December 16th, Marshall Urist sold 20,000 shares of Royalty Pharma stock. The shares were sold at an average price of $38.32, for a total transaction of $766,400.00.
• On Friday, December 5th, Marshall Urist sold 23,334 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $913,526.10.
• On Friday, December 5th, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The shares were sold at an average price of $39.15, for a total transaction of $714,174.30.
• On Monday, December 1st, Marshall Urist sold 23,333 shares of Royalty Pharma stock. The shares were sold at an average price of $39.93, for a total transaction of $931,686.69.
• On Monday, December 1st, Marshall Urist sold 18,242 shares of Royalty Pharma stock. The stock was sold at an average price of $39.90, for a total transaction of $727,855.80.

Royalty Pharma Price Performance

---

---

RPRX stock opened at $40.36 on Wednesday. The stock's 50 day moving average price is $39.30 and its 200 day moving average price is $37.36. The firm has a market cap of $23.30 billion, a P/E ratio of 30.58, a PEG ratio of 1.93 and a beta of 0.43. The company has a debt-to-equity ratio of 0.89, a quick ratio of 3.48 and a current ratio of 3.48. Royalty Pharma PLC has a 1 year low of $29.66 and a 1 year high of $41.70.

• 1 Trial, 2 Franchises: Zenas Stock Climbs on Landmark Data

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $1.17 earnings per share for the quarter, topping the consensus estimate of $1.11 by $0.06. Royalty Pharma had a return on equity of 26.36% and a net margin of 32.51%.The company had revenue of $609.29 million during the quarter, compared to the consensus estimate of $765.01 million. On average, sell-side analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 20th will be issued a $0.235 dividend. This is a positive change from Royalty Pharma's previous quarterly dividend of $0.22. The ex-dividend date is Friday, February 20th. This represents a $0.94 dividend on an annualized basis and a yield of 2.3%. Royalty Pharma's payout ratio is currently 66.67%.

Wall Street Analyst Weigh In

• 4 Healthcare Stocks With Massive Gains—and More to Come

A number of equities analysts have recently weighed in on RPRX shares. Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a research report on Friday, November 28th. Weiss Ratings downgraded Royalty Pharma from a "buy (b-)" rating to a "hold (c+)" rating in a report on Saturday, October 25th. The Goldman Sachs Group assumed coverage on Royalty Pharma in a research note on Tuesday, September 30th. They set a "buy" rating and a $42.00 price target on the stock. Morgan Stanley decreased their price objective on Royalty Pharma from $55.00 to $54.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Finally, TD Cowen lifted their price objective on Royalty Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a research report on Thursday, December 11th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $45.60.

Check Out Our Latest Analysis on Royalty Pharma

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Company raised its quarterly dividend to $0.235, which can boost yield and appeal to income-focused investors and signals confidence in cash generation. Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.235
• Positive Sentiment: Royalty struck a deal with Teva on a potential vitiligo drug, adding a new partnered asset that could generate future royalties if successful — positive for pipeline diversification and long‑term royalty upside. Teva inks deal with Royalty Pharma on potential vitiligo drug
• Positive Sentiment: Management presented a business update at the J.P. Morgan Healthcare Conference—provides transparency on deal flow, portfolio performance and near‑term catalysts that can support investor confidence. Royalty Pharma to Highlight Accomplishments and Provide Business Update at 44th Annual J.P. Morgan Healthcare Conference
• Neutral Sentiment: Full transcript of the J.P. Morgan presentation is available — useful for parsing management commentary for guidance or deal timing, but the transcript itself doesn't change fundamentals. Royalty Pharma plc (RPRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Reported short interest data appears anomalous (zeros/NaN) and likely reflects a reporting glitch rather than a substantive change in short positioning; not a clear driver of price.
• Negative Sentiment: CFO Terrance P. Coyne sold 69,582 shares (≈$2.67M) in early January, reducing his stake materially — large insider sales can be interpreted as profit‑taking or reduced insider conviction and often pressures sentiment. SEC Form 4 (Terrance P. Coyne)
• Negative Sentiment: EVP Marshall Urist sold 20,000 shares (~$815.6k) on Jan. 9, trimming his position by 25%—another sizeable insider sale that may add short‑term selling pressure. SEC Form 4 (Marshall Urist)

Hedge Funds Weigh In On Royalty Pharma

Large investors have recently bought and sold shares of the stock. Smartleaf Asset Management LLC grew its stake in shares of Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock valued at $31,000 after buying an additional 790 shares during the period. USA Financial Formulas acquired a new position in Royalty Pharma in the second quarter valued at $32,000. Financial Consulate Inc. purchased a new stake in Royalty Pharma during the third quarter valued at about $35,000. Larson Financial Group LLC grew its position in Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 306 shares during the period. Finally, MassMutual Private Wealth & Trust FSB increased its stake in Royalty Pharma by 42.1% during the second quarter. MassMutual Private Wealth & Trust FSB now owns 1,358 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 402 shares during the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Company Profile

(Get Free Report)

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Featured Stories

• Five stocks we like better than Royalty Pharma
• “Ominous day” coming to stocks…
• Punch these codes into your ordinary brokerage account
• The Crash Has Already Started (Most Just Don’t See It Yet)
• Trump Planning to Use Public Law 63-43: Prepare Now
• A month before the crash

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].